KaloBios Pharmaceuticals develops proprietary, patient-targeted, first-in-class monoclonal antibodies using its Humaneered™ technology. The company has three clinical programs: KB001-A (anti-PcrV) for Pseudomonas aeruginosa in cystic fibrosis (partnered with Sanofi Pasteur, with KaloBios retaining CF rights), KB003 (anti-GM-CSF) for severe asthma, and KB004 (anti-EphA3) for hematologic malignancies and solid tumors. KB001-A and KB003 are planned for Phase 2 clinical trials, and KB004 is in a Phase 1 study. The company says proceeds from recent financings will be used to advance these clinical development programs and for general corporate purposes. KaloBios is headquartered in South San Francisco, Calif. Recent financings provide up to approximately $35 million in gross proceeds to support its near-term clinical activities. KaloBios develops engineered non-human antibodies for therapeutic use in humans. The company is actively advancing clinical programs, running seven first- and second-phase trials for two drugs and working on a third, newer drug. Its programs target patients with cystic fibrosis and autoimmune disorders such as asthma. KaloBios has taken $20 million in its fourth round of venture funding to support clinical development. The financing round was co-led by Mitsubishi UFJ Capital and Genzyme Ventures, with participation from prior investors including MPM Capital, Alloy Ventures, GBS Ventures, Sofinnova Ventures, Singapore Bioinnovations, 5AM Ventures and Lotus Bioscience Ventures. The company is based in South San Francisco, Calif. KaloBios develops drugs based on monoclonal antibodies that target specific cells or proteins. Its lead candidate is an antibody against granulocyte macrophage colony-stimulating factor (GM-CSF), intended to treat immune-related diseases such as rheumatoid arthritis and asthma. The company raised $20 million in a third funding round. The financing will allow KaloBios to support clinical testing of two antibodies and to move a third into human tests. The round was led by Lehman Brothers and included MPM Capital, Sofinnova Ventures, Alloy Ventures, 5AM Ventures, Singapore Bioinnovations, and Lotus BioScience Ventures.

Total raised

$50M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Sep 2012